Recipharm installs dedicated production line for prostate cancer depot

By Dan Stanton

- Last updated on GMT

Image: iStock/naruedom
Image: iStock/naruedom

Related tags Manufacturing Cancer Pharmaceutical formulation

Recipharm has installed a dedicated production line to make prostate cancer drug Liproca Depot for Swedish pharma firm LIDDS AB.

Contract manufacturing organisation (CMO) Recipharm commenced negotiations to make LIDDS’ Liproca Depot in April 2015​, and began developing a process for the commercial production the modified-release cancer candidate later that year.

And yesterday Recipharm announced a dedicated manufacturing line adapted for GMP production has been established at its facility in Solna, Sweden.

“This was a very challenging project as it required the purchase, installation and qualification of several pieces of equipment,”​ Torkel Gren, general manager of the facility told in-Pharmatechnologist.com.

“Some of this equipment has not been used in the pharma industry before. Recipharm has experience in setting up new types of technology for GMP manufacture so this was a project that we were well suited for.”

In total seven pieces of new equipment have been installed to make Liproca Depot, Gren revealed though he could not comment on either the cost of the project or which company footed the bill.

Liproca Depot comprises of a modified-release formulation of 2-hydroxyflutamid, prepared as a paste, delivered in a pre-filled container/syringe, which also acts as mixing equipment of the paste prior to injection.

Using LIDDS’ NanoZolid technology, the local administration could offer advantages over current prostate cancer treatments including fewer side effects, reduced dosing frequency and improved patient compliance.

The manufacturing process consists of three main stages: nanocrystal activation with heat, micronisation and drug dispersion, and drug encapsulation by hydration and isotatic pressure.

According to Gren, line could be used for future LIDDS’ pharmaceutical formulations based on the NanoZolid technology.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers